Company Overview

calQ was founded on a simple, yet profound concept. Given today’s mobile technology, there must be a way to disrupt traditional medical testing with a solution that is portable, rapid, accurate and affordable. According to CEO, Pamela Turbeville, “the concept was formed by a MD during the Ebola virus outbreak in 2007 where nothing worked except smartphones.” calQ then turned the idea of using smartphones to read medical tests into a truly disruptive technology that is faster and less expensive than current labs and most importantly portable.

Product/Service Overview

calQ has developed a groundbreaking point of care diagnostic platform using existing smartphones to test and read diagnostic results in the doctor’s office, hospital, home or rural locations without easy access to health care facilities. Our proprietary app reads and analyzes test strip results. This versatile patented technology can go from testing for congenital hypothyroidism (CHT) in infants in developing countries to testing thyroid, cortisol, vitamin D, A1C and a host of other analytes in blood, saliva or urine in a fast, accurate and affordable manner. Our platform accommodates most phones and can read tests anywhere, anytime, affordably without traditional infrastructure or electricity. We have 6 issued patents so far on this technology and are far ahead of any potential competitors. We can conduct a thyroid stimulating hormone (TSH) test for less than $5 in about 10 minutes.

Market Opportunity

The global clinical laboratory market is estimated to be $261 Bn. Our markets can be segmented into Medical outside the US in developing countries with government and non-government entities looking to provide testing to people not currently served due to cost or location. The first use is to test and then treat newborns for Congenital Hypothyroidism (CHT), thus eliminating the most easily treated cause of mental retardation. calQ has already contracted with a Big Pharma in India to initially purchase over $11mn of this novel technology for newborn testing, has an initial contract of $200k/year in Bangladesh and has been contacted by several other countries to provide units for testing newborns. calQ recently received a CE Mark allowing for the sale of our products in Europe, Asia and many countries outside the U.S. As far as the US, we are currently preparing the final application to the FDA for clearance of our TSH test. We are in the process of building sales and marketing teams for each of the medical market as well as other additional tests using the calQ platform including hemoglobin, cortisol, cannabis (THC), STDs. Our revenue model: sales of smartphone hardware, sales of the test strips required to run each test, monthly subscription for use of the app, advertising on the app, sale of geo-mapping and other data.

Management Team

Pamela Turbeville, CEO and Founder was the CEO of Navistar Financial Corp after serving as an executive with WR Grace, Nortel and J-M. With a BSc, MSc and MBA, she has over a decade of experience in start-ups.

Brian Hickie, CPA, serves as CFO and CIO. As the prior CIO of McKesson, he also brings industry and start-up experience.

Anand Kumar, Director of Business Development India, is an engineer with a wealth of experience in management.

Randall Polson, PhD, Director of R & D (acting) has developed innovative, proprietary technology for calQ for 8 years.

Strong, experienced advisory board

<table>
<thead>
<tr>
<th>Ellen Carnahan</th>
<th>Dan Santy-Founder Santy. Marketing Communications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julie Silverstein</td>
<td>Michael T. Hull, President - Iron Horse Diagnostics, Inc.</td>
</tr>
<tr>
<td>Michael Rossman</td>
<td>Daniel Ketcherside-Ketch 22 Consulting</td>
</tr>
<tr>
<td>Adam Bruss</td>
<td>Cindy Minon Ketcherside Ketch 22 Consulting</td>
</tr>
</tbody>
</table>

i-calQ, Corp
7525 E. Gainey Ranch Road #173
Scottsdale, AZ 85258
Pamela.turbeville@i-calQ.com
(855) 589-9503
www.i-calQ.com